Johnson & Johnson Stock Issued During Period, Value, Other
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Johnson & Johnson stock issued during period, value, other for fiscal 2025 was $6.01B, a 151.53% increase from fiscal 2024.
- Johnson & Johnson stock issued during period, value, other for fiscal 2024 was $2.39B, a 5.54% decline from fiscal 2023.
- Johnson & Johnson stock issued during period, value, other for fiscal 2023 was $2.53B, a 26.48% decline from fiscal 2023.
- Johnson & Johnson stock issued during period, value, other for fiscal 2023 was $3.44B, a 20.83% increase from fiscal 2022.
| Period end | Stock Issued During Period, Value, Other 3 month | Stock Issued During Period, Value, Other 12 month |
|---|---|---|
| 2025-12-28 | $6.01B 10-K · filed 2026-02-11 | |
| 2024-12-29 | $2.39B 10-K · filed 2026-02-11 | |
| 2023-12-31 | $2.53B 10-K · filed 2026-02-11 | |
| 2023-01-01 | $3.44B 10-K · filed 2025-02-13 | |
| 2022-01-02 | $2.85B 10-K · filed 2024-02-16 | |
| 2021-01-03 | $3.15B 10-K · filed 2023-02-16 | |
| 2019-12-29 | $2.69B 10-K · filed 2022-02-17 | |
| 2018-12-30 | $3.06B 10-K · filed 2021-02-22 | |
| 2017-12-31 | $3.16B 10-K · filed 2020-02-18 | |
| 2017-01-01 | $3.31B 10-K · filed 2019-02-20 | |
| 2016-01-03 | $2.50B 10-K · filed 2018-02-21 | |
| 2014-12-28 | $2.93B 10-K · filed 2017-02-27 | |
| 2013-12-29 | $3.37B 10-K · filed 2016-02-24 | |
| 2012-12-30 | $3.25B 10-K · filed 2015-02-24 | |
| 2012-01-01 | $1.65B 10-K · filed 2014-02-21 | |
| 2011-01-02 | $1.79B 10-K · filed 2013-02-22 | |
| 2010-01-03 | $1.38B 10-K · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |